Two months after Merck acquired Seattle-based biotech Immune Design for $300 million, the president of Merck Research Laboratories, Roger Perlmutter, says the city’s life science community has plenty more to… Read More
Merck, one of the world’s largest drugmakers, agreed to buy Seattle-based biotechnology company Immune Design for $300 million in cash. The deal’s price tag, at $5.85 per share, amounted to… Read More
Trading on the NASDAQ under the ticker IMDZ, Seattle biotech company Immune Design today priced its initial public offering at $12 per share and raised $60 million. The company, which is… Read More
Seattle biotechnology company Immune Design, which is working on novel technologies that activate the body’s immune system to fight cancer, set its IPO range at $12 o $14 per share.… Read More
Immune Design Corp., a Seattle biotechnology company developing technologies to activate the body’s immune system to fight cancer, has filed to raise $60 million through an initial public offering. The… Read More
Immune Design has reeled in $32.5 million in venture capital financing, with plans to raise up to $16.5 million more in the series C round if certain milestones are met.… Read More